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Abstract
Background: Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a natural antioxidant polyphenol able to exert a wide
range of biological effect on several tissues. Despite its important beneficial properties, it has a low water solubility,
which limits its therapeutic applications in humans. Resveratrol also acts as a phytoestrogen that modulates
estrogen receptor (ER)-mediated transcription. In addition, it has been shown that ovarian tissues benefit greatly
from vitamin D3, which exerts its beneficial effects through VDR receptors.
The aim was to evaluate the cooperative effects of resveratrol combined with vitamin D3 on ovarian cells and
tissues and some other organs as well. Moreover, the modulation of specific intracellular pathways involving ER and
VDR receptors has been studied.
Methods: The experiments were performed both in vitro and in vivo, to analyze cell viability, radical oxygen
species production, signal transductions through Western Blot, and resveratrol quantification by HPLC.
Results: Cell viability, radical oxygen species production, and intracellular pathways have been studied on CHO-K1
cells. Also, the relative mechanism activated following oral intake in female Wistar rats as animal model was
investigated, evaluating bioavailability, biodistribution and signal transduction in heart, kidney, liver and ovarian
tissues. Both in in vitro and in vivo experiments, resveratrol exerts more evident effects when administered in
combination with vitD in ovarian cells, showing a common biphasic cooperative effect: The role of vitamin D3 in
maintaining and supporting the biological activity of resveratrol has been clearly observed. Moreover, resveratrol
plus vitamin D3 blood concentrations showed a biphasic absorption rate.
Conclusions: Such results could be used as a fundamental data for the development of new therapies for
gynecological conditions, such as hot-flashes.
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Background
Resveratrol (3,5,4′-trihydroxy-trans-stilbene, RES) is a nat-
ural antioxidant polyphenolic compound belonging to stil-
bene phytoalexins, a sub-group of non-flavonoid phenolic
compounds [1, 2]. RES is contained in various vegetables
such as berries, grapes, peanuts, besides red wine [3]. Par-
ticularly, red wine is the main source of RES, but a recent
study discovered that peanut sprouts contain abundant
RES both in cis and trans isoforms [4, 5]. Cis- and trans-
isomers of RES coexist in plants and in wine. RES is rapidly
metabolized in vivo and has a low water solubility, which
reduces the rate-absorption in cells [6] reducing oral bio-
availability [7]. The effectiveness of orally administered
RES depends on its absorption, metabolism and tissue dis-
tribution. At intestinal level, RES is absorbed by passive dif-
fusion or through the formation of complexes with
membrane transporters, whereas in the bloodstream it can
be found as glucuronide, sulfate, or free as well [8]. In
some studies performed on animal models, the peak con-
centrations of trans-RES occur in blood and serum very
rapidly, about 15 min from the beginning of the adminis-
tration [9]. Human studies on the absorption and bioavail-
ability of RES used a single oral dose of 25mg [10, 11], but
it was difficult to detect non-metabolized RES in
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circulating plasma. In some studies, RES solubility has
been increased by the use of ethanol (50mg/mL) or other
organic solvents [9]. Moreover, researchers have recently
attempted to improve RES chemical stability, water-
dispersibility, bioavailability, permeability through blood–
brain barrier (BBB) and therapeutic efficacy by using
nanostructure-based drug delivery systems [12–14]. A
number of epidemiologic studies have shown that RES has
beneficial effects in preventing various pathologic condi-
tions ranging from cardiovascular diseases to cancer [15].
As reported by in vitro studies, RES can inhibit cell prolif-
eration, induce apoptosis and block cell cycle progression
in numerous types of human cancer cell lines, such as
those of the colon, skin, breast, lung, prostate and liver, as
well as pancreas [10]. In addition, in a few in vivo experi-
mental models of colon and esophagus cancers the effect-
iveness of oral doses of RES was shown [16, 17]. RES acts
as a phytoestrogen modulating estrogen receptor (ER)-me-
diated transcription [18]. The estrogenic role of RES is im-
portant since a variety of RES-sensitive tissues are ER-
positive and the two ER subtypes in mammals, ERα and
ERβ, exhibit different tissue-specific expression profiles
[19]. Specifically, effects of RES on ER include anti-
inflammatory effects such as protection from trauma-
hemorrhage-induced injury and suppression of
Interleukin-6 (IL-6) expression in the liver, intestine and
cardiovascular system [20]. However, in contrast to other
ERα agonists, resveratrol does not induce proliferation of
mammary or uterine tissues, allowing it to be taken as a
dietary supplement. RES binds and increases the transcrip-
tional activity of estrogen receptors (ERα and ERβ) at 50–
100 μM [19–22]. RES displays a great affinity for ER behav-
ing as either agonist or antagonist in a cell- and tissue-
specific manner [23]. This is important to explain the ef-
fectiveness of RES in reducing the number of vasomotor
episodes and the intensity of hot flashes (HF), with the
transition from moderate/severe to mild symptoms in
78.6% of patients [24]. RES has the characteristics to be an
alternative therapy in the treatments of HF in menopause.
The common incidence of hot flashes is around 75% and
presently hormone replacement therapy is the gold stand-
ard in the management of moderate to severe vasomotor
symptoms associated with menopause. RES has also been
associated with anti-inflammatory effects, particularly in
tissues that contain a large number of estrogen receptors,
through this connection has been studied, but there are
few studies on the mechanisms activated [25, 26].
In recent years, vitamin D has seen growing interest
among researchers, especially due to the presence of its
receptor (VDR) in many tissues and organs. It has been
demonstrated that in ovarian tissues a high density of
VDR is present as well [27, 28] and vitamin D3 (the active
form of vitamin D, 1,25-dihydroxyvitamin D3, vitD) acts
through intracellular mechanisms similar to what
observed for RES [29]. The role of vitD in cellular growth
regulation is demonstrated by its ability to arrest cells in
the G1/G0 phase of the cell cycle, and by up-regulating
p21, a powerful tumor suppressor gene. Thus, vitD can
control cell division and proliferation [30]. VitD also has
important anti-proliferative, anti-angiogenic and pro-
differentiative effects in a wide range of cancers [31].
Interestingly enough, many of the bioeffects of resveratrol
overlap with reported benefits from high circulating levels
of vitD. Thus, given the ability of vitD to elicit a wide
range of bio-effects via transcriptional regulation, evaluat-
ing resveratrol in the context of VDR signaling is of par-
ticular interest to help in elucidating the molecular
pathways involved by these two dietary lipophilic sub-
stances in optimizing healthspan and well aging [30]. The
potential for resveratrol to modulate vitamin D receptor
signaling has recently been postulated [32, 33]. There is an
overall structural symmetry and parallel configuration of
resveratrol and known VDR ligands, which could suggest
that resveratrol might serve as a low-affinity VDR ligand
with the ability to activate VDR. Intriguingly, several tar-
gets emerge such as eNOS, cyclooxygenase, and Akt kin-
ase, all of which are likewise regulated by vitD [34]. VitD
can exert its beneficial effects through several important
signaling pathways mediated through genomic and non-
genomic mechanisms [35]. Finally, vitD exerts beneficial
effects on ovarian tissues preventing ROS-derived cellular
injury [28]. Therefore, since these two substances have
similar effects on ovarian cells, some form of interaction
in exerting effects can be hypothesized. This could lead to
interesting results for future clinical use in menopause-
related conditions like hot flashes. For this reason, the aim
of this study was to evaluate the biological effects of RES
combined with the active form of vitD in order to increase
the absorption of RES using vitD that it is able to activate
the same intracellular pathways of RES on cultured ovar-
ian cells and tissue.
Methods
Cell culture
CHO-K1 (Chinese Hamster Ovary cell), purchased from
Lonza (Basel), were cultured in Dulbecco’s modified Ea-
gle’s medium: Nutrient Mixture F-12 (DMEM-F12;
Sigma, Milan, Italy) supplemented with 10% fetal bovine
serum (FBS, Sigma, Milan, Italy), 2 mM glutamine and
1% penicillin/streptomycin (Sigma, Milan, Italy) and in-
cubated at 37 °C, 5% CO2, and 95% humidity [36]. When
the cells reached 80–90% of confluence were seeded for
different experiments; 1 × 104 and 2.5 × 104 cells were
plated in a 96-well for MTT test and ELISA activation
assay, respectively; 1 × 105 cells plated on 24-well plates
to analyzed ROS production; for Western blot analysis
and SOD activity the cells were seeded in 6 wells and
maintained until 85% of confluence.
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Experimental protocol in vitro
The cells before treatments were placed overnight in Dul-
becco’s modified Eagle’s medium (DMEM; Sigma, Milan,
Italy) without red phenol and FBS in incubator at 37 °C,
5% CO2, and 95% humidity. The cells were treated with a
range of Resveratrol (RES) 10-100 μM to determine an
optimal concentration; 50 μM was chosen and its efficacy
verified in a time-course study (from 2 min to 48 h). The
RES concentration was chosen basing on previous studies
about the therapeutic range of ovarian evidence [37, 38]
and on the experiments of dose-response study. RES was
prepared in lipidic solvent that was also tested alone in
CHO-K1 cultures. The cooperative activity of RES with
vitD (active form of vitamin D, 1,25-dihydroxyvitamin
D3), was also tested, evaluating the effects of the co-
stimulation with RES 50 μM and vitD 100 nM [39] in
CHO-K1 cells during time.
MTT test
MTT-based In Vitro Toxicology Assay Kit (Sigma-Al-
drich) was performed as described in literature [40] to
determine cell viability after stimulations. Cells were in-
cubated in DMEM without red phenol 0% FBS with 1%
MTT dye for 2 h at 37 °C in incubator [41] and then cell
viability was determined measuring the absorbance
through a spectrometer (VICTORX4 multilabel plate
reader) at 570 nm with correction at 690 nm. The re-
sults were obtained comparing the results to control
cells (100% viable).
ROS production
The rate of superoxide anion production was determined
as a superoxide dismutase-inhibitable reduction of cyto-
chrome C, following a standard technique [41, 42]. In both
treated and untreated cells, 100 μl of cytochrome C were
added and in another sample, 100 μL of superoxide dismut-
ase were also added for 30 min in incubator (all substances
from Sigma-Aldrich). The absorbance was measured at
550 nm by spectrometer (VICTORX3 Multilabel Plate
Reader) and the O2 was expressed as nanomoles per re-
duced cytochrome C per microgram of protein.
Akt/ERK activation assay
The InstantOne™ ELISA is specifically engineered for ac-
curate measurement of phosphorylated ERK 1/2 and
AKT in cell lysates, following the manifacturer’s instruc-
tions (Thermo-Scientific). Cells at the end of treatments
were lysated with 100 μL Cell Lysis Buffer Mix, shaken
for 10 min at RT and 50 μL/well of each sample were
tested in InstantOne ELISA microplate strips including
the 50 μL/well Positive Control Cell Lysate and 50 μL/
well negative control. At each well 50 μL of prepared
Antibody Cocktail were added and the strips incubated
for 1 h at room temperature on a microplate shaker and
washed 3 times with 200 μL/well of Wash Buffer (1X).
At the end, 100 μL of the Detection Reagent were added
to each well and after 20 min the reaction was stopped
adding to each well 100 μL of Stop Solution. The strips
were measured by a spectrometer (VICTOR X4 multila-
bel plate reader) at 450 nm. The results were expressed
as means Absorbance (%) compared to control.
SOD activity assay
Cayman’s Superoxide Dismutase Assay Kit utilizes a
tetrazolium salt for detection of superoxide radicals gen-
erated by xanthine oxidase and hypoxanthine. The SOD
assay measures all three types of SOD (Cu/Zn, Mn, and
FeSOD). The cells and tissue were lysed after treatments
following manufacturer’s instructions (Cayman). In a 96
well, at every sample of 10 μl were added 200 μl of the
diluted Radical Detector. At the same time, a standard
curve was prepared (0.05–0.005 U/ml). Then, 20 μl of
diluted Xanthine Oxidase were added at all wells and
the plate mixed for 30 min at RT and then the absorb-
ance measured through a spectrometer (VICTOR X4
multilabel plate reader) at 480 nm. The results were
expressed as a means (%) compared to control.
Western blot of cell lysates
CHO-K1 cells were lysed in ice Complete Tablet Buffer
(Roche) supplemented with 2 mM sodium orthovanadate,
1 mM phenylmethanesulfonyl fluoride (PMSF; Sigma-
Aldrich), 1:50 mix Phosphatase Inhibitor Cocktail (Sigma-
Aldrich) and 1:200 mix Protease Inhibitor Cocktail (Cal-
biochem). 35 μg of proteins of each sample were resolved
on 10% SDS-PAGE gel. Polyvinylidene difluoride mem-
branes (PVDF, GE, Healthcare Europe GmbH, Milan,
Italy) were incubated overnight at 4 °C with specific pri-
mary antibody: anti-VDR receptor (1:400, Santa-Cruz)
and anti-ERβ (1:500, Santa-Cruz). Protein expression was
normalized to the specific total protein (if possible) and
verified through β-actin detection (1:5000; Sigma-Aldrich)
and expressed as a mean ± SD (%).
Animal model
Female Wistar rats weighing 300 to 350 g (n = 94) pur-
chased from Envigo++++ (Bresso, Italy), were housed in a
room at a constant temperature of 25 °C on a 12-h/12-h
light/dark cycle with food and water available ad libitum.
All experiments were conducted in accordance with
local ethical standards and prospectively approved by
the University OPBA (Organismo Preposto al Benessere
degli Animali, Animal Wellness Committee). Experi-
mental protocols were approved by national guidelines
(Ministero della Salute authorization number 914/2015-
PR) and in accordance with Guide for the Care and Use
of Laboratory Animals (National Institutes of Health
publication 86–23, 1985 revision).
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In vivo experimental protocol
In order to study the bioavailability 0.5 mg RES were ad-
ministrated by gavage following a standard technique
[43, 44]; the quantity of RES was calculated by the con-
version formula (animal-man) approved by FDA [45].
For each animal, anesthesia was performed via isoflurane
(1.2–1.5 Mean Alveolar Concentration) in oxygen and
gavage was carried out using probe-ended stainless-steel
gastric tubes (80 × 1.5 mm, length × outer diameter).
After treatment, rats were placed in individual cages and
housed separately for the duration of the study and daily
monitored. The animals were randomized in different
groups: n = 36 treated with RES lipophilic formula;
n = 36 with RES plus vitD 0.4 μg lipophilic formula;
n = 18 treated with vitD 0.4 μg alone; n = 4 untreated
(control) and sacrificed at T0. Time-point for each treat-
ment (2, 5, 15, 30, 60, 180, 360, 720, 1440 min) was con-
ducted in triplicates. The animals were euthanized by
CO2 asphyxiation at each time point and the organs
(liver, stomach, intestine, heart, kidneys and ovaries)
were withdrawn to evaluate biodistribution of the differ-
ent RES formulations, and to evaluate the ovarian tissue
integrity by Western-blot. In addition, blood samples
used for RES determination by HPLC analysis, the oxy-
gen radical species (ROS) and vitD quantification (by
ELISA kit) were collected at each time-point using CBC
tubes to obtain plasma by centrifugation at 3000 rpm for
15 min at room temperature.
Plasma vitamin D quantification
Vitamin D3, the active form of vitamin D, is very short-
lived and rapidly metabolized to the deactivated forms
24,25(OH)2D3 and 1,24,25(OH)3D3. For this reason a
competitive EIA assay kit has been used that primarily de-
tects the more metabolically stable forms, 25(OH)D3 and
25(OH)D2 (Cayman’s Vitamin D EIA Kit). At the end of
each time point, plasma samples were collected using
EDTA-Na2 as an anticoagulant, centrifuged for 15 min at
1000×g at 4 °C within 30 min and then the supernatant
used immediately. Before adding to wells, the SABC work-
ing solution and TMB substrate were equilibrate for at
least 30 min at room temperature and the strips of the
plate washed twice before adding standard, sample and
control. For the quantification it is necessary to plot a
standard curve including control (zero well). 0.1 ml of
each sample and standard were added into test sample
wells, the plate sealed with a cover and incubated at 37 °C
for 90 min. After the plate content was removed, 0.1 ml of
Biotin- detection antibody work solution was added into
the standard and test sample at 37 °C for 60 min. After
the plate was washed 3 times with Wash buffer 0.1 ml of
SABC working solution into each well was added and the
plate incubated at 37 °C for 30 min. After the plate was
washed 3 more times with Wash buffer 90 μl of TMB
substrate into each well was added and the plate incubated
at 37 °C in dark within 15–30 min. After this time 50 μl of
Stop solution into each well was added and the absorb-
ance measured at 450 nm in a microplate reader immedi-
ately after adding the stop solution.
Total plasma antioxidant capacity
The concentration of radical oxygen species (ROS) in
plasma was measured in a 96-well plates using the Antioxi-
dant Assay kit (Cayman) following the manufacturer’s in-
structions [46]. In brief, 10 μl of Metmyoglobin and 150 μl
of Chromogen per well were added in plasma and standard
samples (Trolox in Assay buffer from 0 mM to 0.33 mM)
and the reactions started adding 40 μl of Hydrogen Perox-
ide Working Solution to all the wells. The 96-well plate was
covered, mixed for 5 min at room temperature and the ab-
sorbance was measured using spectrophotometer (VIC-
TORX4 Multilabel Plate Reader) at 750 nm or 405 nm.
The results were expressed as means ± SD (%).
Western-blot of ovarian tissues
Ovarian tissues were immediately washed with ice 0.9% sa-
line solution (w/v), weighed and homogenized in a volume
of 100 mg tissue/300 μL of lysis buffer (0.1 M Tris, 0.01 M
NaCl, 0.025 M EDTA, 1% NP40, 1% Triton X100, Sigma-
Aldrich, Milan) supplemented with 2 mM sodium orthova-
nadate, 0.1 M sodium fluoride (Sigma-Aldrich, Milan),
1:100 mix of protease inhibitors (Sigma-Aldrich, Milan),
1:1000 phenylmethylsulfonyl fluoride (PMSF; Sigma-
Aldrich, Milan), using an electric potter at 1600 rpm for
2 min. Samples were mixed for 30 min at 4 °C, centrifuged
for 30 min at 13000 rpm at 4 °C and 40 μg of proteins for
each samples resolved on SDS-PAGE gel at 15%. Proteins
transferred to polyvinylidene fluoride membranes (PVDF,
GE Healthcare Europe GmbH, Milan, Italy) were incubated
overnight at 4 °C with specific primary antibody: anti-VDR
receptor (1:400, Santa-Cruz), anti-ERβ (1:500, Santa-Cruz),
anti-cyclin-D1 (1:1000, Euroclone, Milan, Italy). Protein ex-
pression was normalized and verified through β-actin
detection (1:5000; Sigma-Aldrich) and expressed as a
mean ± SD (%).
RES quantification in CHO-K1
At the end of stimulations cells were placed in ice and
supernatants were collected in 1.5 ml centrifuge tubes to
determine the rate of extracellular RES. 1 × 106 CHO-
K1 cells at the end of stimulations were washed with
cold 0.9% saline solution, lysed in ice 0.9% saline solu-
tion, mixed for 10 min at 4 °C and centrifuged for
20 min at 13000 rpm at 4 °C. Supernatants were used
for quantification of intracellular RES. Samples were di-
luted with equal volume of acetonitrile, vortexed, centri-
fuged at 13000 rpm for 10 min, and analyzed by HPLC-
UV (Additional file 1).
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RES quantification in rat plasma and tissues
RES quantification in rat plasma and tissue samples (liver,
stomach, intestine, heart, kidneys and ovaries) was carried
out by HPLC-MS analysis. Tissues were homogenized in a
volume of 100 mg tissue/300 μl of ice 0.9% saline solution
(w/v) at 1600 rpm for 2 min and the lysates were mixed for
20 min at 4 °C, and then centrifuged at 13000 rpm for
30 min at 4 °C. Plasma and tissue supernatants were proc-
essed as follows. An aliquot of 50 μl of plasma or tissue
sample was mixed with 50 μl of 1 M of sodium acetate buf-
fer (pH = 5.5) and 2.5 μl of β-glucuronidase/arylsulfatase
from Helix pomatia in a 1.5 ml centrifuge tube. Ethyl acet-
ate (600 μl) was added, then sample was extracted by vor-
texing (40s), and centrifuged at 13000 rpm for 10 min. An
aliquot (550 μl) of the organic layer was transferred into
1.5 ml centrifuge tube and evaporated at 45 °C under re-
duced pressure for 40 min. The residue was dissolved in
100 μl of acetone containing the IS (trans-4-hydroxystil-
bene- final concentration, 200 μg/l), 25 μl of 0.1 N NaOH,
and 100 μl of 1 mg/ml Dns-Cl (dansyl chloride) solution in
acetone. Sample was shortly vortexed and heated at 45 °C
for 20 min. After centrifugation (13,000 rpm for 5 min) the
sample was analysed by HPLC-MS (Additional file 1). Cali-
bration curve for RES quantification was prepared by spik-
ing blank matrixes and processed as described above,
except for the addition of β-glucuronidase/arylsulfatase.
Statistical analysis
In vitro results obtained from at least 5 independent ex-
periments conducted in triplicates were expressed as
means ± SD, using One-way ANOVA followed by Bonfer-
roni post hoc test. Values of significance for p < 0,05 were
considered statistically significant. Data collected from in
vivo results obtained from 4 independent experiments
were analyzed by two-way ANOVA and one-way ANOVA
followed by Bonferroni post hoc test and the comparisons
between the two groups were performed using a two-
tailed Student’s t-test. Multiple comparisons between
groups were analyzed by two-way ANOVA followed by a
two-sided Dunnett post-hoc testing. P-value < 0.05 was
considered statistically significant.
Results
Dose-response and time-course study
A dose response and a time-course study were planned to
identify the dose of Resveratrol (RES) able to induce the
maximal effect on cell viability during time. In addition,
these experiments were important to understand the co-
operative effect of RES with vitamin D3 (vitD) during time.
As shown in Fig. 1c RES 50 μM appeared to be the dose
producing the greatest effect (p < 0.05) compared to control
and to other concentrations (10, 25, 100 μM) during all
time periods considered (Fig. 1a–d). This concentration of
RES was maintained for all successive experiments. In
addition, another important finding regarded the reaction
time of RES 50 μM, which appeared as a biphasic curve
that quickly started (at 2 min), confirming its rapid metab-
olism. Its beneficial effect was maintained as long as 3 h.
The combination of RES 50 μM with vitD 100 nM was
able to amplify biological effects with a similar kinetic
reaction to RES alone (p < 0.05); vitD was already able
to stabilize and enhance the effect of RES from 2 min of
treatment (Fig. 2a). Then we observed a stable plateau
phase around 6 h and then effects began to decline for
the following 48 h. For this reason, we have chosen to
study the kinetics ranging from 2 min to 3 h for all suc-
cessive experiments. As shown in Fig. 2b, the radical
oxygen species (ROS) produced by RES alone and com-
bined with vitD appeared to be modulated during time.
In particular, in the first minutes (from 2 to 15 min)
after treatment with RES alone a significant ROS pro-
duction compared to control (p < 0.05) was observed
and the presence of vitD was able to amplify this effect.
This combination was also able to maintain a reduction
of ROS up to 1 h of stimulation (p < 0.05); at 3 h ROS
production was comparable to control (p > 0.05). These
data confirm the beneficial effects previously observed
on cell viability of CHO-K1 cells and the importance of
the combination of RES and vitD to maintain the benefi-
cial effects of RES during time.
Quantification of intracellular RES with or without vitD3
in CHO cells
Since the biological effects of RES were due to its ability
to be absorbed in cells and tissues, the intracellular con-
centration of RES in CHO-K1 during time was deter-
mined by HPLC-UV. As reported in Fig. 3, the absorption
rate of RES combined with vitD was enhanced compared
to RES alone (p < 0.05), in particular in the first 15 min of
stimulation; the maximum effect was observed at 5 min of
stimulation (about 16.7 μM). These findings confirmed
previous data about the cooperative effect of RES plus
vitD; vitD was important to amplify and stabilize the ef-
fects of RES influencing also the level of RES uptake in
ovarian cells. Finally, this time range (from 2 to 15 min) of
stimulation was used to verify the intracellular cascade ac-
tivated by RES alone and combined with vitD.
Analysis of the main intracellular pathways activated by
RES and vitD
In order to assess which intracellular pathways were acti-
vated after intracellular uptake of RES alone and com-
bined with vitD, ERKs, Akt, SOD, ERβ and VDR signaling
were investigated in CHO-K1 cells. As reported in Fig. 4a
and b, the role of MEK1/MAPK and PI3K/Akt pathways
was examined to explain the action mechanism of RES
alone and combined with vitD; MAPK and PI3K signal
transduction pathways are closely associated with the one
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of healthy tissue. To study changes in the activation levels
of proteins associated with cellular signal transduction
according to treatment time, ELISA was performed fol-
lowing treatment for various time periods up to 15 min.
The results confirmed an increase in activation of ERK
and Akt due to RES alone and these effects were amplified
by the presence of vitD. In particular, the results showed
that the activation levels of ERK and Akt started at 2 min
and the maximum effect was observed at 5 min in both
RES alone and combined with vitD compared to control
(p < 0.05) then decreased. These data confirmed the
Fig. 1 Time-course and dose-response study of CHO-K1 viability measured by MTT test. a time-course of RES 10 μM; b time-course of RES 25 μM;
c time-course of RES 50 μM; d time-course of RES 100 μM. Reported data are means ± SD of five independent experiments. * not significant vs
control; point without symbol p < 0.05 vs control. RES = resveratrol. The effect of solvent alone is reported as well
Fig. 2 The cooperative effect of RES and vitD during time on
cell viability and ROS production in CHO-K1 cells. a cell viability
and b ROS production measured during time-course study in
presence of RES and vitD alone and combined. Reported data
are means ± SD in (a) and they are expressed as means ± SD(%)
in (b) of five independent experiments. * not significant vs
control; points without symbol, p < 0.05 vs control. RES = resveratrol
50 μM; vitD = vitamin D3 100 nM; RES + vitD = co-stimulation of RES
50 μM with vitD 100 nM
Fig. 3 Measure of intracellular concentration of RES alone and
combined with vitD in CHO-K1 cells in a time-course study.
Reported data are means ± SD of five independent experiments.
* not significant vs control; points without symbol, p < 0.05 vs
control. RES = resveratrol 50 μM; RES + vitD = co-stimulation of
RES 50 μM with vitamin D 100 nM
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importance of vitD in amplifying the beneficial effects of
RES to maintain healthy tissue. In addition, since the
beneficial effects of RES included its anti-radical action,
two important mechanisms involved such as SOD activity
and ERβ, were also investigated by ELISA and Western
blot respectively. As reported in Fig. 4c, SOD activity was
maintained similar to control, demonstrating the ability of
RES combined with vitD to maintain ROS production low
during time. In addition, these anti-oxidant effects were
obtained via ERβ activation (Fig. 4d); the involvement of
ERβ was observed starting from 2 min after treatment
with RES alone and increasing after 5 min compared to
control (p < 0.05); the presence of vitD amplified
(p < 0.05) all these levels of activations (about 20% at
2 min and 65% at 5 min of RES plus vitD compared to
RES alone), indicating a cooperative activity exerted by
RES and vitD. The importance of combined treatments
with RES and vitD was also confirmed on VDR expression
(Fig. 4e), in which a stable activation of VDR during time
was observed (p < 0.05), indicating its involvement in the
beneficial effects previously observed. Such results indi-
cate that the maintenance of tissue health induced by RES
Fig. 4 Western Blot, densitometric analysis and protein activation of CHO-K1 cells stimulated with RES and vitD alone and together. In a (ERK/
MAPK), b (Akt), c (SOD) activations by ELISA are reported as means ± SD(%) of five independent experiments. In d (ERβ receptor) and e (VDR
receptor) Western blot (on the left) and densitometric analysis (on the right) are reported. In the right column the specific densitometric analysis
is reported and expressed as means ± SD(%) of five independent experiments. * p < 0.05 vs control; ** p < 0.05 vs RES alone; φ p < 0.05 vs vitD;
the bars, p < 0.05 between RES + vitD at different times. RES = resveratrol 50 μM; vitD = vitamin D3 100 nM; RES + vitD = co-stimulation of RES
50 μM with vitD 100 nM
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is mediated through the ERK, Akt, SOD, ERβ and VDR
signal transduction pathways, which can help clarify that
these beneficial effects exerted by vitD are a necessary
condition.
Bioavailability of resveratrol with vitamin D3
Since the biological effects of RES and vitD were reported
in an in vitro study, some additional experiments were
performed to demonstrate their efficacy in in vivo study as
well, starting from bioavailability of RES alone and com-
bined with vitD, following a time-course experiments (2,
5, 60, 180, 360, 720 min). As reported in Fig. 5a on rat
plasma samples, the concentration of RES plus vitD and
RES alone were time-dependent and followed by a bi-
phasic curve. Plasma concentration started to enhance at
2 min (p < 0.05). The plasma of rats treated with RES
alone showed a second peak of RES concentration at 1 h
of treatment (about 20% lower than 2 min) and then the
concentration decreased reaching control values. The
presence of vitD significantly amplified the absorption rate
of RES already in the first 2 min (about 34% compared to
RES alone at 2 min) and obtained the maximum effects at
5 min (about 220% compared to RES alone at 5 min). In
addition, a second peak was extended in time (after 1 h)
because the absorption rate after 5 min was similar to
what observed with RES alone as long as 3 h. At 6 h a sec-
ond peak was shown and then the plasma concentration
decreased leading to control values. This finding about the
second peak supported the hypothesis that RES can be
stored in organs to explain a secondary effect in the long
run. All these data supported the importance of the co-
operative activity of RES and vitD and explained the role
of vitD in supporting the biological activity of RES. As re-
ported in Fig. 5b, the quantification of vitD in plasma
samples showed an increase in quantity of vitD present in
plasma when vitD was administered with RES during
time. These data confirmed the mutual influence of RES
and vitD on the absorption after oral intake. In addition,
the ROS concentration assessment in plasma of rats con-
firmed a positive influence of vitD on anti-radical mech-
anism induced by RES (Fig. 5b) during time; a slow and
progressive decrease starting from 1 h of treatment with
RES combined with vitD was observed and this effect is
aligned with the absorption test at the time the maximum
absorption rate has been reached. All these data explained
the ability of RES plus vitD to rapidly cross the membrane
and to reach target tissues.
Analysis of the intracellular pathways activated in ovarian
tissue
In order to clarify the importance of bioavailability after
oral intake of RES combined with vitD in gynecological
disorders, some intracellular pathways involved in the
biological effects of RES and vitD were also investigated
in ovarian rat tissues during the first minutes (2, 5, 15,
30 min), following the plasmatic changes. As reported in
Fig. 6, a better influence of RES plus vitD than RES
alone (p < 0.05) has been demonstrated by the involve-
ment of Cyclin D1 (Fig. 6a, b), an important regulator of
G1 to S phase progression. The effects of RES plus vitD
started at 5 min compared to RES alone (p < 0.05) and
were maintained during time, indicating an improve-
ment in cell cycle turn-over, important to maintain the
Fig. 5 Bioavailability, vitamin D quantification and ROS production in
in vivo experiments. Female rats (n = 48) were treated with RES
0.5 mg alone (n = 24), combined with vitD 0.4 μg (n = 24) and with
vitD 0.4 μg alone (n = 18) by gavage. The animals were sacrificed at
specific time-points (ranging 2–270 min) and plasma samples were
collected. In a RES plasma concentration (μg/L), in b vitD plasma
quantification and in c the ROS production are reported. The results
are expressed as means ± SD in panel (a) and as means ± SD(%) in
panel (b) of 4 independent experiments. All data p < 0.05 vs control.
RES = resveratrol 0.5 mg; RES + vitD = preparation composed of RES
0.5 mg and vitD 0.4 μg
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integrity of tissue. This finding was supported by a de-
crease in SOD activity (Fig. 6e) observed with RES com-
bined with vitD taken at the same time as Cyclin D1,
compared to RES alone. These improvements of the bio-
logical effects of RES were obtained due to the presence
of vitD, supporting previous data on the cooperative ef-
fects. The mechanism activated by RES plus vitD in-
volved both ERβ (Fig. 6a, c) and VDR receptors (Fig. 6a,
d), as reported. As a matter of fact, RES plus vitD
showed the strongest effect on ERβ starting from 5 min
(p < 0.05) compared to RES alone and on VDR starting
from 2 min (p < 0.05) compared to RES alone. These ef-
fects were maintained during all time of stimulation. All
these findings supported the in vitro results about the
cooperative effect of RES and vitD on ovarian tissue.
Biodistribution of resveratrol with vitamin D3
Another important parameter useful to understand the bio-
logical effects of RES combined with vitD after oral intake
and blood concentration was the biodistribution and accu-
mulation of RES in different organs during time (30, 60,
180, 360, 720 min), such as heart (Fig. 7a), kidney (Fig. 7b),
Fig. 6 Western blot, densitometric analysis and protein activity of ovarian tissue obtained from female rats (n = 32) treated with RES alone (n = 16)
and combined with vitD (n = 16). In the upper (a) an example of Western Blot taken at different time (ranging 2–30 min) of Cyclin D1, ERβ receptor
and VDR receptor is reported. In the downstream the specific densitometric analysis of Cyclin D1 (b), ERβ receptor (c), and VDR receptor (d) is reported
and expressed as means ± SD(%) of 4 independent experiments. In e SOD activity by ELISA was reported as means ± SD(%) of 4 independent
experiments. * p < 0.05 vs control; ** p < 0.05 vs RES alone; the bars, p < 0.05 between RES + vitD at different times. RES = resveratrol 0.5 mg;
RES + vitD = preparation composed of RES 0.5 mg and vitD 0.4 μg
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and liver (Fig. 7c). As reported, the absorption rate in tissue
of RES alone and RES plus vitD was different and time-
dependent, confirming the hypothesis about the activity of
RES in the second peak observed in plasma samples. In
addition, a better efficacy of RES combined to vitD
(p < 0.05) in creating a tissue deposit of RES was confirmed
mainly at 360 min in all organs tested (p < 0.05), indicating
the importance of the combination with vitD to exert a sys-
temic biological effect.
Discussion
In the present study, it has been demonstrated that RES
exerts more evident effects when administered in com-
bination with vitD in ovarian cells, therefore showing a
cooperative effect. Specifically, in CHO-K1 cells RES
combined with vitD: a) showed biphasic biological
effects; b) increased the number of viable cells; c) de-
creased ROS production; d) modulated, in a time-
dependent manner, the levels of ERK/MAPK and Akt/
PI3K. Resveratrol appeared to act involving ERK and
Akt pathways via attenuation of ROS generation since it
is combined with vitamin D3. These findings allow us to
confirm the antioxidant effect of RES, which is mediated
by SOD modulation, as shown by data collected in the
in vitro experiments of this study. As regards the bi-
phasic response observed, after the early effect, found at
2 min, a decrease was present probably due to the rapid
metabolism of RES and then the effect on cell viability
showed a significant rise that lasted as long as 3 h. To
explain this finding, it can be hypothesized that an acti-
vation of long-latency intracellular metabolic pathways
has occurred. As a matter of fact, a biphasic RES re-
sponse has also been observed in other studies [47, 48].
The observation that beneficial effects of RES on cul-
tured ovarian cells are enhanced by the co-stimulation
with vitD is novel and important and it underlines the
existence of a proper regulation essential to sustain tis-
sue homeostasis.
Moreover, it is noteworthy that cooperative effects
exerted by combined RES and vitD have been made pos-
sible through the concurrent involvement of ERβ and
VDR receptors. This finding assumes great relevance for
the ovarian tropism, since it has been demonstrated that
in the ovary, RES exhibits antiproliferative and
androgen-lowering effects on theca-interstitial cells [49].
RES exerts a cytostatic, but not cytotoxic effect in granu-
losa cells, while inhibiting aromatization and VEGF ex-
pression [49]. In addition, RES may increase the
follicular reserve and extend the duration of ovarian life
as an antiaging agent. The results of ongoing clinical tri-
als are expected with impatience [50]. However, RES
studies in ovarian physiology are limited. RES was re-
ported to exert estrogenic effects, increasing the uterine
and ovarian weight [51, 52]. It is a phytoestrogen known
to bind equally to estrogen receptors α and β [22, 51]
and structurally similar to synthetic estrogens. The es-
trogenic agonist activity of resveratrol depends on the
ERE sequence and the type of ER as well [19]. Trans-
genic studies revealed that the ERa subtype mediates
sexual behavior, while ERb is more directly implicated in
ovarian development [52].
Fig. 7 Biodistribution of RES (μg/L) in in vivo experiments. Female
rats (n = 40) were treated with RES 0.5 mg alone (n = 20) and
combined with vitD 0.4 μg (n = 20) by gavage. The animals were
sacrificed at specific time-points (ranging 30–270 min) and heart (a),
kidney (b) and liver (c) were collected. The results are expressed as
means ± SD (μg/L) of 4 independent experiments. * not significant
vs control; point without symbol, p < 0.05 vs control. RES = resveratrol
0.5 mg; RES + vitD = preparation composed of RES 0.5 mg and
vitD 0.4 μg
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Resveratrol can exert different actions in different cell
types. The anti-proliferative activities of resveratrol may
arise from its ability to interfere with nuclear factor-κB
(NF-κB), p38 MAPK and phosphatidylinositol 3-kinase/Akt
survival pathways [53], resulting in the suppression of DNA
synthesis and cell proliferation, the inhibition of cell cycle
progression and the induction of apoptosis. It is also im-
portant to note that the effects of RES on cellular growth
are not universally inhibitory and, in several biological
systems, RES has been shown to protect cells from death
[54–59]. Therefore, the possibility of increasing the effect-
iveness of RES by associating vitD may be of clinical rele-
vance in conditions linked to theca-interstitial cell
hyperplasia, androgen excess and abnormal angiogenesis,
such as PCOS, targeting most of the endocrine and meta-
bolic underpinnings of PCOS. In PCOS, the typically en-
larged ovaries are characterized by thecal and stromal
hyperplasia [60]. This ovarian enlargement is associated
with excessive ovarian androgen production and the disrup-
tion of menstrual cyclicity. Improvement of ovarian func-
tion, with restoration of ovulation and fertility, was
observed with surgical reduction of ovarian size and/or par-
tial destruction of ovarian tissues by procedures such as
wedge resection and laparoscopic ovarian drilling [61, 62].
In addition to the new findings on essential molecular
targets and signaling mechanisms triggered by RES and
vitD, another important information is about bioavail-
ability. The issue of bioavailability is determined by its
rapid elimination and the fact that despite its highly ef-
fective absorption, the first hepatic step leaves little free
RES. Indeed, only free RES can even bind to plasma pro-
teins that could serve as a reservoir [8]. The in vivo
phase of this study has shown that in ovarian tissue, RES
exerts its effects in a cooperative manner with vitD. Spe-
cifically, in rat, RES in combination with vitD showed: a)
a biphasic absorption rate not only in the ovary but also
in the heart, kidney and liver tissues, related to blood
concentration; b) increased bioavailability and biodistri-
bution; c) reduced ROS production confirmed by SOD
activity; d) modulation in a time-dependent manner of
the levels of Cyclin D1 sustaining tissue homeostasis; e)
a cooperative effect through the involvement of the ERβ
receptor and VDR. The transport into bloodstream of
RES was nonlinear during time, suggesting metabolism
to be rate-limiting with respect to bioavailability. The
second peak of plasma level after the oral dose may be
due to enteric recirculation of conjugated metabolites by
reabsorption after intestinal hydrolysis. In general, the
doses of RES have been higher in animals than in
humans. However, as in humans, the oral bioavailability
in animals seems to be low and the metabolism involves
both glucuronidation and sulfation [10]. For these rea-
sons the dose of RES considered effective in human has
been kept [24].
The execution of animal experiments is justified by the
need of studying the rate of absorption of RES. After ad-
ministration, RES undergoes a glucuronidation. There is
evidence that the major form of RES transferred across
the rat intestinal epithelium into the bloodstream is its
glucuronide metabolite [63]. Therefore, an efficient carrier
system should drive RES through the epithelial stratum to
the bloodstream thus shortening its permeation time and
metabolic turnover [7]. So, the aim of these additional ex-
periments was to demonstrate that the effects observed in
the in vivo experiments could be related with the previ-
ously observed in vitro effects with RES plus vitD.
Another novelty in this study is the observation that the
cooperative mechanism has also been demonstrated in the
intestinal absorption phase. This is clearly stated in a new
set of in vivo experiments where the intracellular activated
cascade mechanism after absorption demonstrates the co-
operative mechanism. It is important to note that until
now it was assumed that the RES also acted as a VDR
agonist, but primarily in anti-tumor mechanisms [30].
Due to its estrogenic action, RES appears to be an opti-
mal candidate for use in gynecological diseases, especially
in the treatment of hot flashes (HF) associated with meno-
pause. Vasomotor symptoms (VMS), including the hot
flush, are amongst the commonest symptoms of the
menopause transition period. Hot flushes are a heat dissi-
pation response characterized by flushing and sweating,
probably triggered by a narrowing of the thermoneutral
zone in the hypothalamus and an increased central secre-
tion of noradrenaline. The neuroendocrine changes asso-
ciated with a hot flush may have significance far beyond
the immediate distress and discomfort experienced at the
time [64]. Despite various therapeutic solutions for the
treatment of HF have been proposed, the results obtained
do not show evidence of effectiveness in the use of phy-
toestrogens [65]. Although there are no human studies re-
garding the effects of resveratrol on menopausal signs and
symptoms, a recent trial demonstrated that resveratrol
may enhance mood and cognition in postmenopausal
women [66]. Indeed, RES is effective in reducing the num-
ber of vasomotor episodes and the intensity of HF, with
the transition from moderate/severe to mild symptoms in
78.6% of patients. Resveratrol has the characteristics to be
an alternative therapy in the treatment of HF in meno-
pause [24]. RES seems to act as an agonist/antagonist
mixed α and β estrogen receptors. In fact, it binds β and α
receptors with a comparable affinity, yet lower compared
to estradiol. RES is different from other phytoestrogens,
which bind the β receptor with greater affinity than the α
receptor. Furthermore, it shows an estradiol antagonist
behavior only to the α receptor. This would explain the
beneficial effect of RES in the gynecological therapy [24].
Summing up, RES has been the focus of many recent in
vitro and in vivo studies because of its pleiotropic
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biological activities [51, 67]. Its small molecular structure
and polyphenolic character provides RES with antioxidant
properties and multiple biological activities that are well
documented when studied in vitro. However, some dis-
crepancies have been observed in in vivo studies where ef-
fects may have low magnitude, mainly because of the
limited distribution in tissues [8]. For this reason, research
on RES uptake, cellular destination, metabolism and sta-
bility of the natural compound and of its metabolites as
well is needed to elucidate its biological activity and it
would be crucial to take advantage from its noteworthy
properties [68]. For this reason, the scientific community
is looking for innovative strategies to implement the bio-
availability through drug delivery systems such as the use
of nanoemulsion-based delivery systems [69] or through
the ability to interact in a cooperative way with other mol-
ecules such as vitD.
However, the interplay between resveratrol and vita-
min D must be further elucidated if the true potential of
their clinical applications is to be revealed.
Conclusions
In conclusion, this study demonstrated for the first time a
cooperative effect of RES and vitD on ovarian cell and tis-
sue, mediated by main physiological intracellular mecha-
nisms. Such results could be used as a fundamental data
for the development of new therapies for gynecological
conditions, such as menopause-related hot-flashes.
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